• 1. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 2. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 3. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 4. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 5. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Quinoline carboxylic acids

Introduction to 6,7-Difluoro-1-[(1S,2S)-2-fluorocyclopropyl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (CAS No. 127199-00-2)

6,7-Difluoro-1-[(1S,2S)-2-fluorocyclopropyl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, identified by its CAS number 127199-00-2, is a sophisticated organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the quinoline class of heterocyclic structures, which are well-documented for their broad spectrum of biological activities. The presence of fluorine atoms and a chiral cyclopropyl group in its molecular framework imparts unique physicochemical properties and potential therapeutic benefits.

The molecular structure of 6,7-Difluoro-1-[(1S,2S)-2-fluorocyclopropyl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid features a quinoline core substituted with two fluorine atoms at the 6th and 7th positions. The (1S,2S)-2-fluorocyclopropyl side chain introduces steric and electronic modifications that can influence binding interactions with biological targets. This configuration makes the compound a promising candidate for further exploration in drug discovery.

In recent years, the incorporation of fluorine atoms into pharmaceutical molecules has been extensively studied due to their ability to enhance metabolic stability, binding affinity, and pharmacokinetic profiles. The fluorine atoms in 6,7-Difluoro-1-[(1S,2S)-2-fluorocyclopropyl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid are strategically positioned to modulate electronic effects and potentially improve interactions with enzymes or receptors. Additionally, the chiral cyclopropyl group contributes to the compound's stereochemical diversity, which is crucial for developing enantiomerically pure drugs with optimized efficacy and minimal side effects.

Current research in medicinal chemistry has highlighted the quinoline scaffold as a versatile platform for designing antimicrobial, antiviral, anticancer, and anti-inflammatory agents. The structural features of 6,7-Difluoro-1-[(1S,2S)-2-fluorocyclopropyl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid align well with these therapeutic areas. For instance, studies have demonstrated that fluorinated quinolines can exhibit enhanced activity against bacterial enzymes such as DNA gyrase and topoisomerase IV. These enzymes are critical for bacterial DNA replication and transcription, making them attractive targets for developing novel antibiotics.

The (1S,2S)-2-fluorocyclopropyl moiety in the compound may also contribute to its bioactivity by influencing conformational flexibility and binding affinity. Chiral centers are known to play a pivotal role in drug-receptor interactions, and the presence of multiple stereocenters in this molecule suggests potential for developing enantiomerically enriched derivatives with improved pharmacological properties.

Recent advancements in computational chemistry have enabled the rapid screening of molecular libraries for hits with desired biological activities. Virtual screening techniques combined with molecular docking studies have been employed to evaluate the binding potential of 6,7-Difluoro-1-[(1S,2S)-2-fluorocyclopropyl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid to various protein targets. Preliminary results indicate that this compound may interact with enzymes involved in cancer cell proliferation and apoptosis pathways.

The carboxylic acid group at the 3-position of the quinoline ring provides an additional site for chemical modification. This functionality can be exploited to link the compound to other pharmacophores or to enhance its solubility through esterification or amidation reactions. Such modifications are commonly employed in drug development to optimize pharmacokinetic parameters and improve therapeutic efficacy.

In conclusion,6,7-Difluoro-1-[(1S,2S)-2-fluorocyclopropyl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (CAS No. 127199-00-2) represents a structurally intriguing molecule with potential applications in pharmaceutical research. Its unique combination of fluorine substitution and chiral centers makes it a valuable scaffold for designing novel therapeutic agents. Further experimental investigations are warranted to elucidate its biological activity and explore its potential as a lead compound for drug development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)